BIODESIX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.22 USD | -1.21% |
|
-5.43% | -33.70% |
| 04-09 | Biodesix, Inc. announced that it has received $34.999422 million in funding | CI |
| 04-05 | Top Midday Decliners | MT |
Chart calendar Biodesix, Inc.
9588742b3d7dcdaa3b722f.tR-FPnAtbGbh5tZBnz46FcCnV-VA2EkCNeb5VY5esTw.3C7aeS9sKVbTjaEs53VXTfifB6MxoSpPW6-eLeUshEzHebd_OHcLV7bSvQ~237776ecf42171e6cbabcad4ff0a5a03
Upcoming events on Biodesix, Inc.
Past events on Biodesix, Inc.
| 2024-04-09 16:30 | American Association for Cancer Research Meeting - Abstract Number : 6474 |
| 2024-04-09 13:45 | American Association for Cancer Research Meeting - Biomarkers |
| 2024-04-08 16:30 | American Association for Cancer Research Meeting - Abstract Number : 3706 |
| 2024-03-04 10:30 | TD Cowen Health Care Conference |
| 2024-03-01 08:30 | Q4 2023 Earnings Call |
| 2024-03-01 06:00 | Q4 2023 Earnings Release |
| 2023-11-29 16:30 | Piper Sandler Healthcare Conference |
| 2023-11-16 15:00 | Canaccord Genuity MedTech Diagnostics and Digital Health and Services Forum |
| 2023-11-07 16:30 | Q3 2023 Earnings Call |
| 2023-11-07 16:01 | Q3 2023 Earnings Release |
| 2023-10-11 18:00 | CHEST Meeting - Comparison of a High Specificity Blood-Based Biomarker |
| 2023-10-10 19:00 | CHEST Meeting - Reduction of Diagnostic Interventions on Benign Lung Nodules |
| 2023-10-10 18:00 | CHEST Meeting - Real-World Impact of a Blood-Based Integrated Classifier |
| 2023-10-09 18:00 | CHEST Meeting - Novel Lung Cancer Biomarker Proteomic Testing on Lung |
| 2023-09-12 | H.C. Wainwright Global Investment Conference |
| 2023-09-12 12:15 | Morgan Stanley Global Healthcare Conference |
| 2023-09-11 06:00 | International Association for the Study of Lung Cancer World Lung Conference |
| 2023-09-10 05:30 | International Association for the Study of Lung Cancer World Lung Conference |
| 2023-08-23 | American Association for Bronchology and Interventional Pulmonology Conference |
| 2023-08-09 16:00 | Canaccord Genuity Growth Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 24,6 | 45,6 33,5 35.99% | 54,5 54,6 -0.19% | 38,2 39,3 -2.78% | 49,1 50,1 -2.05% | 65,3 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | -20,0 -25,8 22.21% | -37,8 -39,6 4.72% | -47,0 -44,3 -6% | -38,0 -36,8 -3.4% | 0,00 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -22,9 -28,1 18.44% | -40,9 -42,1 2.74% | -50,6 -48,2 -4.86% | -41,3 -41,4 0.17% | -29,5 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -31,4 -33,8 7.35% | -43,2 -43,8 1.4% | -65,4 -59,2 -10.55% | -52,1 -51,8 -0.62% | -39,5 |
|
Net income Million USD | Released Forecast Spread | -30,7 | -31,4 -33,8 7.35% | -43,2 -43,8 1.4% | -65,4 -59,2 -10.55% | -52,1 -52,2 0.16% | -39,8 |
|
EPS USD | Released Forecast Spread | -21,3 | -6,48 -1,27 -410.24% | -1,58 -1,58 -0.16% | -1,55 -1,45 -7.27% | -0,64 -0,66 2.54% | -0,40 |
| Announcement Date | 02/10/20 | 16/03/21 | 14/03/22 | 06/03/23 | 01/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 7,22 7,20 0.33% | 6,55 6,47 1.26% | 11,0 8,83 23.96% | 11,1 10,2 9.25% | 9,61 10,8 -10.76% | 9,06 8,70 4.09% | 11,9 11,7 1.91% | 13,5 14,4 -5.99% | 14,7 15,6 -5.97% | 14,2 | 15,7 | 17,0 | 18,4 | 18,4 |
|
EBITDA Million USD | Released Forecast Spread | -10,8 -12,6 14.1% | |||||||||||||
|
EBIT Million USD | Released Forecast Spread | -11,7 -12,6 7.31% | -14,4 -12,1 -19.34% | -11,6 -12,5 6.99% | -10,6 -12,9 17.43% | -13,9 -11,9 -17.21% | -16,4 -14,5 -12.92% | -10,9 -14,3 23.59% | -7,17 -11,3 36.53% | -6,87 -7,80 11.92% | -11,8 | -8,20 | -5,40 | -4,70 | -8,80 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -13,3 -13,7 2.94% | -15,6 -13,6 -14.6% | -15,8 -15,8 -0.15% | -13,7 -14,3 4.2% | -20,3 -14,2 -43.22% | -18,7 -17,1 -9.37% | -13,4 -16,7 20.02% | -10,9 -13,7 20.08% | -9,14 -10,1 9.51% | -14,1 | -10,5 | -7,70 | -7,10 | -11,1 |
|
Net income Million USD | Released Forecast Spread | -13,3 -13,7 2.94% | -15,6 -13,6 -14.6% | -15,8 -15,8 -0.15% | -13,7 -14,3 4.2% | -20,3 -14,2 -43.22% | -18,7 -17,1 -9.37% | -13,4 -16,7 20.02% | -10,9 -13,7 20.08% | -9,14 -10,1 9.51% | -14,1 | -10,5 | -7,70 | -7,10 | -11,1 |
|
EPS USD | Released Forecast Spread | -0,49 -0,49 0.51% | -0,50 -0,43 -17.65% | -0,40 -0,47 13.98% | -0,34 -0,33 -3.82% | -0,35 -0,28 -26.13% | -0,24 -0,24 -1.41% | -0,17 -0,21 17.74% | -0,14 -0,15 6.67% | -0,10 -0,11 9.09% | -0,15 | -0,10 | -0,09 | -0,08 | -0,11 |
| Announcement Date | 14/03/22 | 11/05/22 | 04/08/22 | 03/11/22 | 06/03/23 | 11/05/23 | 07/08/23 | 07/11/23 | 01/03/24 | - | - | - | - | - |
| 2024-05-03 07:00 | FULGENT GENETICS, INC.: Q1 2024 Earnings Release |
| 2024-05-05 | OPKO HEALTH, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-05-07 | RADNET, INC.: Q1 2024 Earnings Release |
| 2024-05-07 | SYNLAB AG: Q1 2024 Earnings Release |
| 2024-05-08 | FLEURY S.A.: Q1 2024 Earnings Release |
| 2024-05-09 | H.U. GROUP HOLDINGS, INC.: Q4 2023 Earnings Release |
| 2024-05-09 | BML, INC.: Q4 2023 Earnings Release |
| 2024-05-09 | GC CELL CORPORATION: Q1 2024 Earnings Release (Projected) |
| 2024-05-13 | METROPOLIS HEALTHCARE LIMITED: Q4 2024 Earnings Release (Projected) |
| 2024-05-16 | DR. LAL PATHLABS LIMITED: Q4 2024 Earnings Release (Projected) |
Past sector events for Biodesix, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- BDSX Stock
- Calendar Biodesix, Inc.
